Overall survival (OS) for the training set (left) and the validation set (right) of patients with advanced systemic mastocytosis (AdvSM). Patients in both sets are grouped by (A and B) SRSF2, ASXL1, and RUNX1 (S/A/R) mutation–based stratification, (C and D) the clinical risk score (CRS), and (E and F) the mutation-adjusted risk score (MARS) (G) OS and (H) leukemia-free survival of all patients with AdvSM (training and validation sets) by MARS. NR, not reached.